This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: April 29, 2002
Last updated: July 18, 2006
Last verified: July 2006
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.

Condition Intervention Phase
Metastases Cancer Drug: ALIMTA Drug: folic acid Drug: multi-vitamins Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Resource links provided by NLM:

Further study details as provided by Eli Lilly and Company:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic or cytologic diagnosis of metastatic or locally advanced cancer
  • Prior chemotherapy is allowed
  • Adequate bone marrow, liver and kidney function

Exclusion Criteria:

  • Prior treatment with ALIMTA
  • Brain metastasis
  • Pregnancy or breast feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00034463

United States, Texas
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
San Antonio, Texas, United States
Sponsors and Collaborators
Eli Lilly and Company
  More Information Identifier: NCT00034463     History of Changes
Other Study ID Numbers: 1310
Study First Received: April 29, 2002
Last Updated: July 18, 2006

Keywords provided by Eli Lilly and Company:
metastatic cancer

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Folic Acid
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on September 25, 2017